ISOFOL.ST
Isofol Medical AB (publ) [ISOFOL.ST] Stock Forecast
Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
RSI : 000
ISOFOL.ST Stock Summary
Top 10 Correlated ETFs
ISOFOL.ST
Top 10 Correlated Stocks
ISOFOL.ST
In the News
ISOFOL.ST Financial details
Company Rating
-
Market Cap
117.74M
Income
-37.04M
Revenue
1.08M
Book val./share
-
Cash/share
-
Dividend
-
Dividend %
-
Employees
3
Optionable
No
Shortable
Yes
Earnings
08 May 2024
P/E
-2.12
Forward P/E
-
PEG
0.28
P/S
47.49
P/B
0.87
P/C
-
P/FCF
-1.38
Quick Ratio
7.61
Current Ratio
7.92
Debt / Equity
-
LT Debt / Equity
-
-
-
EPS (TTM)
-0.23
EPS next Y
-
EPS next Q
-
EPS this Y
-76.29%
EPS next Y
-
EPS next 5Y
-
EPS last 5Y
-
Revenue last 5Y
-
Revenue Q/Q
-
EPS Q/Q
41.75%
-
-
-
-
SMA20
-
SMA50
-
SMA100
-50%
Inst Own
-
Inst Trans
-
ROA
-35%
ROE
-37%
ROC
-0.43%
Gross Margin
100%
Oper. Margin
-2214%
Profit Margin
-2066%
Payout
-
Shs Outstand
-
Shs Float
-
-
-
-
-
Target Price
-
52W Range
0.45-1.24
52W High
-
52W Low
-
RSI
36
Rel Volume
2.68
Avg Volume
392.55K
Volume
1.05M
Perf Week
0.18%
Perf Month
-7.88%
Perf Quarter
-53.68%
Perf Half Y
-48.79%
-
-
-
-
Beta
1.534
-
-
Volatility
0.02%, 0.02%
Prev Close
4.37%
Price
0.8245
Change
3.65%
Company Profile
- Volume Average 392.55K
- Market Capitalization 117.74M
- Employee 3
- CEO Mr. Petter Segelman Lindqvist
- Headquarters Gothenburg,SE
- IPO Date 2017-04-04
-
Website
https://isofolmedical.com 
Isofol Medical AB (publ), a clinical stage biotech company, develops, commercializes, and sells oncology drugs in Sweden and internationally. The company develops arfolitixorin, which is in phase 3 clinical trial for the treatment of advanced colorectal cancer. It has strategic collaborations with Recipharm, Merck & Cie, and Sahlgrenska University Hospital. The company was incorporated in 2008 and is headquartered in Gothenburg, Sweden.
